RT Journal Article SR Electronic T1 Two-Stage Adaptive Pooling with RT-qPCR for COVID-19 Screening JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.07.05.20146936 DO 10.1101/2020.07.05.20146936 A1 Anoosheh Heidarzadeh A1 Krishna Narayanan YR 2020 UL http://medrxiv.org/content/early/2020/07/07/2020.07.05.20146936.abstract AB We propose two-stage adaptive pooling schemes, 2-STAP and 2-STAMP, for detecting COVID-19 using real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) test kits. Similar to the Tapestry scheme of Ghosh et al., the proposed schemes leverage soft information from the RT-qPCR process about the total viral load in the pool. This is in contrast to conventional group testing schemes where the measurements are Boolean. The proposed schemes provide higher testing throughput than the popularly used Dorfman’s scheme. They also provide higher testing throughput, sensitivity and specificity than the state-of-the-art non-adaptive Tapestry scheme. The number of pipetting operations is lower than state-of-the-art non-adaptive pooling schemes, and is higher than that for the Dorfman’s scheme. The proposed schemes can work with substantially smaller group sizes than non-adaptive schemes and are simple to describe. Monte-Carlo simulations using the statistical model in the work of Ghosh et al. (Tapestry) show that 10 infected people in a population of size 961 can be identified with 70.86 tests on the average with a sensitivity of 99.50% and specificity of 99.62%. This is 13.5x, 4.24x, and 1.3x the testing throughput of individual testing, Dorfman’s testing, and the Tapestry scheme, respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis material is based upon work supported by the National Science Foundation (NSF) under Grant CCF-2027997.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None of the results require IRB clearance. No experiments were performed on clinical data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo clinical data were used.